insitro is a machine learning-enabled drug discovery and development company creating a new approach for target and drug discovery. insitro is uncovering genetic targets and new therapeutic hypotheses by integrating multimodal data from human cohorts and cellular models with the power of AI and machine learning to increase the therapeutic probability of success. These insights provide the starting point for discovering new molecules, which are either built with in-house, AI-enabled drug discovery platforms or with partners that extend insitro’s impact. With more than $700 million in capital raised to date, insitro is building a “pipeline through platform” with a focus on metabolic disease and neuroscience. Approaching the clinic, insitro aims to deploy its AI models to run smaller, better powered trials, enrolling the patients who can benefit most.